Cargando…

COVID-19: the Risk to Athletes

PURPOSE OF REVIEW: The COVID-19 pandemic has had a profound impact on athletics, and the question of safely resuming competitive sports at all levels has been a source of significant debate. Concerns regarding myocarditis and the risk of arrhythmias and sudden death in athletes have prompted heighte...

Descripción completa

Detalles Bibliográficos
Autores principales: Goergen, Jack, Bavishi, Aakash, Eimer, Micah, Zielinski, Allison R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519743/
https://www.ncbi.nlm.nih.gov/pubmed/34690485
http://dx.doi.org/10.1007/s11936-021-00941-2
_version_ 1784584515181608960
author Goergen, Jack
Bavishi, Aakash
Eimer, Micah
Zielinski, Allison R.
author_facet Goergen, Jack
Bavishi, Aakash
Eimer, Micah
Zielinski, Allison R.
author_sort Goergen, Jack
collection PubMed
description PURPOSE OF REVIEW: The COVID-19 pandemic has had a profound impact on athletics, and the question of safely resuming competitive sports at all levels has been a source of significant debate. Concerns regarding myocarditis and the risk of arrhythmias and sudden death in athletes have prompted heightened attention to the role of cardiovascular screening. In this review, we aim to comprehensively outline the cardiovascular manifestations associated with COVID-19 infection, to discuss screening, diagnosis, and treatment strategies, and to evaluate the current literature on the risk to athletes and recommendations regarding return-to-play. RECENT FINDINGS: COVID-19 is known to cause myocarditis, with presentations ranging from subclinical current or prior infection detected on cardiac MRI imaging, to fulminant heart failure and shock. While initial data early in the pandemic suggested that the risk of myocarditis could be significant even in patients with nonsevere COVID-19 infection, recent studies suggest a very low prevalence of clinically significant disease in young athletes. SUMMARY: While COVID-19 can have significant cardiovascular manifestations, recent data demonstrate that a screening approach guided by severity of COVID-19 infection and cardiovascular symptoms allows the majority of athletes to safely return to play in a timely manner. We must continue to tailor our approach to screening athletes as knowledge grows, and further research on the longitudinal cardiovascular effects of COVID-19 is needed.
format Online
Article
Text
id pubmed-8519743
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-85197432021-10-18 COVID-19: the Risk to Athletes Goergen, Jack Bavishi, Aakash Eimer, Micah Zielinski, Allison R. Curr Treat Options Cardiovasc Med Sports Cardiology (M Wasfy, Section Editor) PURPOSE OF REVIEW: The COVID-19 pandemic has had a profound impact on athletics, and the question of safely resuming competitive sports at all levels has been a source of significant debate. Concerns regarding myocarditis and the risk of arrhythmias and sudden death in athletes have prompted heightened attention to the role of cardiovascular screening. In this review, we aim to comprehensively outline the cardiovascular manifestations associated with COVID-19 infection, to discuss screening, diagnosis, and treatment strategies, and to evaluate the current literature on the risk to athletes and recommendations regarding return-to-play. RECENT FINDINGS: COVID-19 is known to cause myocarditis, with presentations ranging from subclinical current or prior infection detected on cardiac MRI imaging, to fulminant heart failure and shock. While initial data early in the pandemic suggested that the risk of myocarditis could be significant even in patients with nonsevere COVID-19 infection, recent studies suggest a very low prevalence of clinically significant disease in young athletes. SUMMARY: While COVID-19 can have significant cardiovascular manifestations, recent data demonstrate that a screening approach guided by severity of COVID-19 infection and cardiovascular symptoms allows the majority of athletes to safely return to play in a timely manner. We must continue to tailor our approach to screening athletes as knowledge grows, and further research on the longitudinal cardiovascular effects of COVID-19 is needed. Springer US 2021-10-15 2021 /pmc/articles/PMC8519743/ /pubmed/34690485 http://dx.doi.org/10.1007/s11936-021-00941-2 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Sports Cardiology (M Wasfy, Section Editor)
Goergen, Jack
Bavishi, Aakash
Eimer, Micah
Zielinski, Allison R.
COVID-19: the Risk to Athletes
title COVID-19: the Risk to Athletes
title_full COVID-19: the Risk to Athletes
title_fullStr COVID-19: the Risk to Athletes
title_full_unstemmed COVID-19: the Risk to Athletes
title_short COVID-19: the Risk to Athletes
title_sort covid-19: the risk to athletes
topic Sports Cardiology (M Wasfy, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8519743/
https://www.ncbi.nlm.nih.gov/pubmed/34690485
http://dx.doi.org/10.1007/s11936-021-00941-2
work_keys_str_mv AT goergenjack covid19therisktoathletes
AT bavishiaakash covid19therisktoathletes
AT eimermicah covid19therisktoathletes
AT zielinskiallisonr covid19therisktoathletes